Stem is trading 5.32% down at $2.85, with no fresh company announcement explaining the October 27 decline.
- The board’s October 26 strategic-alternatives review included a possible sale or merger; Stem cautioned there is no timetable or assurance of a transaction.
- NYSE non-compliance disclosed October 23 remains relevant background, but Stem said it has no immediate effect on continued trading. Broader indexes were higher and do not explain the decline.